✦ LIBER ✦

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

✍ Scribed by Yang, H.; Higgins, B.; Kolinsky, K.; Packman, K.; Bradley, W. D.; Lee, R. J.; Schostack, K.; Simcox, M. E.; Kopetz, S.; Heimbrook, D.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[Methods and Principles in Medicinal Che

✍ Lackey, Karen; Roth, Bruce D. 📂 Article 📅 2013 🏛 Wiley-VCH Verlag GmbH & Co. KGaA ⚖ 277 KB

Overexpression of ATP-binding cassette t

✍ Wu, Chung-Pu; Sim, Hong-May; Huang, Yang-Hui; Liu, Yen-Chen; Hsiao, Sung-Han; Ch 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 1006 KB

215 Anti-tumoral effects of the multi-ta

✍ A. Valverde; A. Gómez-España; V. Hernández; J. Jiménez; L.M. López-Sánchez; M.T. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

QS282. BRAF Mutation Status, But not ERK

✍ Jonathan C. Samuel; Elizabeth D. Routh; Channing J. Der; Jen Jen Yeh 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 48 KB

329 Antitumor activity in preclinical xe

✍ S.L. Winski; M.A. Bittner; P. Briner; E.N. Brown; A.R. Cooke; A. Crew; C. Hidden 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 154 KB

205 Distinct inhibitory properties of ME

✍ M. Belvin; L. Berry; J. Chan; K. Hoeflich; B. Liu; S. Malek; M. Merchant; C. Orr 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB